Kala Pharmaceuticals Appoints Andrew I. Koven to Board of Directors
“Andrew’s experience in senior leadership roles, success in business
development, and extensive legal expertise within the biotech and
pharmaceutical industry will be an asset in providing guidance and
strategy to our company as we advance potential new treatments for eye
diseases,” said
Mr. Koven has served as President and Chief Business Officer at
“I am honored to join the Board of Directors at this exciting and transformative time in Kala’s history,” said Mr. Koven. “I am very much looking forward to working with the company on its continued mission to develop innovative and important therapies for patients with eye diseases.”
About Kala Pharmaceuticals, Inc.
Kala is a
biopharmaceutical company focused on the development and
commercialization of therapeutics using its proprietary
mucus-penetrating particle (MPP) technology, with an initial focus on
the treatment of eye diseases. Kala has applied the MPP technology to
create a corticosteroid designed for ocular applications, resulting in
two product candidates in Phase 3 clinical development, KPI-121 1.0% for
the treatment of inflammation and pain following ocular surgery and
KPI-121 0.25% for the temporary relief of the signs and symptoms of dry
eye disease.
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, that involve substantial risks and
uncertainties including statements regarding the development and
regulatory status of the company's product candidates, including KPI-121
1.0% for the treatment of inflammation and pain following ocular surgery
and KPI-121 0.25% for the temporary relief of the signs and symptoms of
dry eye disease. All statements, other than statements of historical
facts, contained in this press release, including statements regarding
our strategy, future operations, future financial position, future
revenue, projected costs, prospects, plans and objectives of management,
are forward-looking statements. The words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,”
“target,” “potential,” “will,” “would,” “could,” “should,” “continue”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. We may not actually achieve the plans, intentions or
expectations disclosed in our forward-looking statements, and you should
not place undue reliance on our forward-looking statements. Actual
results or events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements we make. For a
discussion of the risks and uncertainties, and other important factors,
any of which could cause our actual results to differ from those
contained in the forward-looking statements, see the "Risk Factors"
section, as well as discussions of potential risks, uncertainties and
other important factors, in our Quarterly Reports on Form 10-Q and other
filings we make with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20171002005393/en/
Source:
Investors and Media:
MacDougall Biomedical Communications
Cammy
Duong, 781-591-3443
cduong@macbiocom.com